10
Participants
Start Date
January 31, 2007
Primary Completion Date
May 31, 2008
Study Completion Date
May 31, 2008
Tigecycline
All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
CPL Associates Investigational Site, Cumberland
CPL Associates Investigational Site, Marietta
CPL Associates Investigational Site, Huntsville
Lead Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
CPL Associates
OTHER